Papillary Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PPL018 MIFTS: 46	Papillary Adenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma ¹² ¹⁵ ⁷²

Infiltrating and Papillary Adenocarcinoma ¹²

Infiltrating Papillary Adenocarcinoma ¹²

Adenocarcinoma, Papillary ⁴⁴

Adenocarcinoma Papillary ⁵⁵

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3112

MeSH ⁴⁴ D000231

NCIt ⁵⁰ C2853 C7438

SNOMED-CT ⁶⁸ 4797003 64524002

UMLS ⁷² C0001420 C1321863

Sources

Summaries for Papillary Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to aggressive digital papillary adenocarcinoma and gastric papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Cytoskeletal Signaling and MicroRNAs in cancer. The drugs Letrozole and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Wikipedia : ⁷⁵ Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Sources

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)

#	Related Disease	Score	Top Affiliating Genes
1	aggressive digital papillary adenocarcinoma	34.6	MUC1 CEACAM5
2	gastric papillary adenocarcinoma	34.3	TP53 ERBB2
3	eccrine papillary adenocarcinoma	34.1	PGR KRT7
4	papillary serous adenocarcinoma	31.4	TP53 PGR NKX2-1 KRT7 BRCA1
5	papillary adenoma	30.8	VIM NKX2-1 KRT7
6	rete testis adenocarcinoma	30.5	NKX2-1 CEACAM5
7	adenocarcinoma	30.5	TP53 MUC1 ERBB2 CDH1
8	fallopian tube adenocarcinoma	30.4	ERBB2 BRCA2 BRCA1
9	cystadenoma	30.4	PGR MUC1 KRT7
10	hidradenoma	30.3	VIM MUC1 KRT7
11	oncocytoma	30.2	VIM MUC1 KRT7
12	adenofibroma	30.2	VIM MUC16 MUC1
13	pulmonary sclerosing hemangioma	30.2	NKX2-1 KRT7
14	mucinous adenocarcinoma	30.2	NKX2-1 MUC1 KRT7
15	endosalpingiosis	30.0	PGR MUC1 KRT7
16	cervical adenocarcinoma	29.9	TP53 PGR KRT7 ERBB2
17	spiradenoma	29.8	TP53 MUC1 KRT7
18	alveoli adenoma	29.8	NKX2-1 KRT7
19	endocervical adenocarcinoma	29.8	VIM TP53 KRT7
20	pseudo-meigs syndrome	29.8	MUC16 CDH1
21	bronchiolo-alveolar adenocarcinoma	29.6	NKX2-1 KRT7 CDH1
22	endometrial adenocarcinoma	29.5	TP53 PGR KRT7 ERBB2
23	sclerosing hemangioma	29.5	PGR NKX2-1 MUC1 KRT7
24	renal cell carcinoma, papillary, 1	29.5	TP53 KRT7 ERBB2
25	barrett esophagus	29.4	TP53 KRT7 ERBB2
26	mucoepidermoid carcinoma	29.3	MUC1 KRT7 ERBB2 CEACAM5
27	adenosquamous carcinoma	29.3	TP53 NKX2-1 MUC1 KRT7
28	cholecystitis	29.3	TP53 MUC1 CDH1
29	serous cystadenocarcinoma	29.3	TP53 PGR MUC16 ERBB2
30	tubular adenocarcinoma	29.3	PGR MUC1 ERBB2 CDH1
31	sweat gland cancer	29.2	TP53 PGR KRT7 ERBB2
32	squamous cell carcinoma	29.1	TP53 MUC1 ERBB2 CDH1
33	renal cell carcinoma, nonpapillary	29.0	VIM NKX2-1 MUC1 KRT7 CDH1
34	mesothelioma, malignant	28.9	VIM NKX2-1 MUC16 MUC1 KRT7 CEACAM5
35	ovarian serous cystadenocarcinoma	28.7	TP53 PGR MUC16 ERBB2
36	transitional cell carcinoma	28.6	TP53 KRT7 ERBB2 CDH1
37	papillary carcinoma	28.6	PGR NKX2-1 MUC1 KRT7 ERBB2 CDH1
38	fallopian tube carcinoma	28.5	TP53 PGR ERBB2 BRCA2 BRCA1
39	in situ carcinoma	28.3	TP53 PGR ERBB2 CDH1 BRCA1
40	gallbladder cancer	28.3	TP53 MUC1 ERBB2 CEACAM5 CDH1
41	carcinosarcoma	28.1	VIM TP53 PGR MUC1 KRT7 ERBB2
42	primary peritoneal carcinoma	27.9	TP53 PGR MUC16 ERBB2 BRCA2 BRCA1
43	cystadenocarcinoma	27.4	TP53 PGR MUC16 MUC1 KRT7 ERBB2
44	pancreatic cancer	27.4	TP53 MUC1 ERBB2 CEACAM5 CDH1 BRCA2
45	gastric adenocarcinoma	27.3	TP53 MUC1 KRT7 ERBB2 CEACAM5 CDH1
46	lung cancer susceptibility 3	27.0	TP53 NKX2-1 MUC1 KRT7 ERBB2 CEACAM5
47	endometrial cancer	26.9	TP53 PGR MUC16 KRT7 ERBB2 CDH1
48	ovarian cancer	26.3	TP53 PGR MUC16 MUC1 KRT7 ERBB2
49	lung papillary adenocarcinoma	12.7
50	fallopian tube papillary adenocarcinoma	12.5

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:

Sources

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.23	BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.09	BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1
2	homeostasis/metabolism	MP:0005376	9.96	BRCA1 BRCA2 CDH1 ERBB2 KRT7 MST1R
3	endocrine/exocrine gland	MP:0005379	9.92	BRCA1 BRCA2 CDH1 ERBB2 MST1R NKX2-1
4	embryo	MP:0005380	9.91	BRCA1 BRCA2 CDH1 ERBB2 PGR TP53
5	digestive/alimentary	MP:0005381	9.88	BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 TP53
6	neoplasm	MP:0002006	9.7	BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
7	normal	MP:0002873	9.5	BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
8	reproductive system	MP:0005389	9.28	BRCA1 BRCA2 CDH1 ERBB2 MST1R NKX2-1

Sources

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

6436030 5284616 46835353

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Everolimus

Approved

Phase 2

159351-69-6

6442177 70789204

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

93860 387447

Azacitidine

Approved, Investigational

Phase 2

320-67-2

9444

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Ipilimumab

Approved

Phase 2

477202-00-9

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

Pembrolizumab

Approved

Phase 2

1374853-91-4

Salmon Calcitonin

Approved, Investigational

Phase 2

47931-85-1

16129616

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Olaparib

Approved

Phase 1, Phase 2

763113-22-0

23725625

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Trametinib

Approved

Phase 2

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760 44516822

Lenalidomide

Approved

Phase 1, Phase 2

191732-72-6

216326

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

nivolumab

Approved

Phase 2

946414-94-4

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Tyrosine

Approved, Investigational, Nutraceutical

Phase 1, Phase 2

60-18-4

6057

Tremelimumab

Investigational

Phase 2

745013-59-6

Calcitonin gene-related peptide

Investigational

Phase 2

83652-28-2

MK-1775

Investigational

Phase 2

501-36-0, 955365-80-7

24856436 445154

Cediranib

Investigational

Phase 1, Phase 2

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 1, Phase 2

110-17-8, 110-16-7

444972

Atrasentan

Investigational

Phase 2

173937-91-2, 195733-43-8

159594

Estrogens

Phase 2

Steroid Synthesis Inhibitors

Phase 2

Estrogen Receptor Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Aromatase Inhibitors

Phase 2

Hormones

Phase 2

Antifungal Agents

Phase 2

Immunoglobulin G

Phase 2

Mitogens

Phase 2

Liver Extracts

Phase 2

Endothelial Growth Factors

Phase 2

Histone Deacetylase Inhibitors

Phase 2

Radiopharmaceuticals

Phase 2

Fluorodeoxyglucose F18

Phase 2

Fluorides

Phase 2

Deoxyglucose

Phase 2

Antibodies

Phase 2

Interventional clinical trials:

(show all 33)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas	Unknown status	NCT02283658	Phase 2	Everolimus;Letrozole
2	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
3	Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma	Completed	NCT00134043	Phase 2	vorinostat
4	A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma	Completed	NCT00098813	Phase 2	romidepsin
5	A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma	Completed	NCT00118248	Phase 2	tanespimycin
6	A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma	Completed	NCT00104871	Phase 2	Bortezomib
7	Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation	Completed	NCT00519896	Phase 2	sunitinib malate
8	Sutent Adjunctive Treatment of Differentiated Thyroid Cancer	Completed	NCT00668811	Phase 2	SU011248, Sutent
9	Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy	Completed	NCT01811212	Phase 2	Cabozantinib S-malate
10	Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine	Completed	NCT00085293	Phase 2	Decitabine
11	A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy	Completed	NCT00729157	Phase 2
12	A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors	Recruiting	NCT03037385	Phase 1, Phase 2	pralsetinib (BLU-667)
13	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
14	A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial	Recruiting	NCT03753919	Phase 2	Durvalumab;Tremelimumab
15	A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer	Recruiting	NCT03506048	Phase 2	Lenvatinib
16	Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy	Recruiting	NCT03914300	Phase 2	Cabozantinib;Cabozantinib S-malate
17	Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study	Recruiting	NCT02973997	Phase 2	Lenvatinib
18	Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers	Recruiting	NCT02393690	Phase 2	Selumetinib
19	Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer	Recruiting	NCT03630120	Phase 2	Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
20	A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers	Recruiting	NCT02152995	Phase 2	Trametinib
21	A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Active, not recruiting	NCT02101775	Phase 2	Adavosertib;Gemcitabine Hydrochloride
22	Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer	Active, not recruiting	NCT01116648	Phase 1, Phase 2	Cediranib Maleate;Olaparib
23	A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma	Active, not recruiting	NCT01723202	Phase 2	dabrafenib;trametinib
24	Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers	Active, not recruiting	NCT00381641	Phase 2	Sunitinib;Sunitinib Malate
25	Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer	Active, not recruiting	NCT01208051	Phase 1, Phase 2	Cediranib Maleate;Lenalidomide
26	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Suspended	NCT02978625	Phase 2
27	A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy	Terminated	NCT00653328	Phase 2	atrasentan hydrochloride;doxil
28	A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors	Completed	NCT01100619	Phase 1	rosiglitazone;XL184
29	A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer	Completed	NCT00470496	Phase 1	HPPH;photodynamic therapy
30	A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake	Completed	NCT01413113	Phase 1	pazopanib hydrochloride
31	Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone	Completed	NCT01441154
32	Studies on Thyroid Nodules and Thyroid Cancer	Recruiting	NCT00001160
33	A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer	Withdrawn	NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Sources

Genetic Tests for Papillary Adenocarcinoma

Sources

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

⁴¹

Thyroid, Lung, Cervix, Lymph Node, Pancreas, Liver, Ovary

Sources

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 1351)

#	Title	Authors	PMID	Year
1	Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? ⁹ ³⁸	Moritani S...Kushima R	18339419	2008
2	Adult thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with thyroid transcription factor-1 expression. ⁹ ³⁸	Wu PY...Chien CY	17967658	2007
3	Case report of renal pelvic adenocarcinoma associated with a renal stone that produced carbohydrate antigen 125 and carbohydrate antigen 19-9. ⁹ ³⁸	Azumi M...Kakizaki H	17933139	2007
4	Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. ⁹ ³⁸	Carrizo F...Luna MA	16084450	2005
5	Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. ⁹ ³⁸	Attanoos RL...Gibbs AR	11895489	2002
6	Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. ⁹ ³⁸	Kawamura T...Suzuki T	11505409	2001
7	[Expression of CD44V6 and nm23-H1 in thyroid papillary adenocarcinoma and lymph node metastasis]. ⁹ ³⁸	Wei Q...Fan S	10681781	1998
8	Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. ⁹ ³⁸	Podnos YD...Manetta A	9234924	1997
9	Cystic brain lesions: cytologic examination and carcinoembryonic antigen assay in fine needle aspirates. ⁹ ³⁸	Pinto MM	8629400	1996
10	[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test]. ⁹ ³⁸	Arao S...Funakoshi A	7474493	1995
11	Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen. ⁹ ³⁸	Takahashi Y...Kusama S	7889481	1995
12	Small cell carcinoma of the stomach: an immunohistochemical and electron microscopic study. ⁹ ³⁸	Morikawa Y...Kakudo K	1333852	1992
13	Establishment of a human chorionic gonadotropin-producing human gastric carcinoma in nude mice. ⁹ ³⁸	Takahashi Y...Mai M	1921405	1991
14	Cardiac tamponade as an initial presentation of papillary carcinoma with psammoma bodies and intranuclear grooves-A diagnostic dilemma. ³⁸	Gochhait D...Penumadu P	31120622	2019
15	[The effective mutation of epidermal growth factor receptor in synchronous multiple primary lung cancers: study of clinical, radiographic and pathological factors]. ³⁸	Wang YJ...Zhao L	31434406	2019
16	Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations. ³⁸	Katayama Y...Takemura Y	31139414	2019
17	Tumor Budding and Other Risk Factors of Lymph Node Metastasis in Submucosal Early Gastric Carcinoma: A Multicenter Clinicopathologic Study in 621 Radical Gastrectomies of Chinese Patients. ³⁸	Du M...Huang Q	31094925	2019
18	Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. ³⁸	Matsubayashi J...Nagao T	30968597	2019
19	Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ³⁸	Huang F...Li J	31287861	2019
20	Nonthyroidal metastatic lesion in thyroid: A missed diagnosis and a lesson learnt. ³⁸	Prameela CG...Sruthi K	31169237	2019
21	Efficacy and safety of endoscopic submucosal dissection for papillary adenocarcinoma-type early gastric cancer. ³⁸	Park JH...Jeong HY	31232966	2019
22	Thyroid-like low-grade papillary adenocarcinoma of nasopharynx. ³⁸	Sourati A...Rakhshan A	31177192	2019
23	[Nasopharyngeal low grade papillary adenocarcinoma with squamous differentiation：a case report]. ³⁸	Ren XY...Zhang CF	31163537	2019
24	Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. ³⁸	Natale C...Krane LS	31395362	2019
25	Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ³⁸	Le QV...Ngo QX	31146581	2019
26	Low-grade papillary adenocarcinoma of nasopharynx. Case report and review of the literature. ³⁸	Garcia-Gomez J...Fernandez-Rodriguez G	30075860	2019
27	Spontaneous pulmonary adenocarcinoma and subcutaneous cavernous hemangiomas arising in a squirrel monkey (Saimiri sciureus). ³⁸	Salleng KJ...Himmel LE	31148179	2019
28	Genetic analysis of digital papillary adenocarcinoma. ³⁸	Nishida H	31025737	2019
29	Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. ³⁸	Surowy HM...Redler S	30472730	2019
30	A Case of Endoscopic Mucosal Resection of Carcinoma in Adenoma at the Minor Duodenal Papilla. ³⁸	Kawashima Y...Mine T	31182951	2019
31	Polypoid gallbladder tumors with a deep hypoechoic area and a conically thickened outermost hyperechoic layer suggest shallow T2 carcinoma. ³⁸	Fujimoto T...Kato Y	31205753	2019
32	A case of lung adenocarcinoma complicated by pulmonary talcosis occurring in a patient employed in the confectionery industry. ³⁸	Kobayashi K...Miyazaki T	30775827	2019
33	The Risk of Misdiagnosing Pulmonary Adenocarcinoma as Traumatic Pseudocyst in a Young Adult. ³⁸	Kamiyoshihara M...Yazawa T	30315800	2019
34	An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report. ³⁸	Takeda M...Nakayama K	31030664	2019
35	[Digital papillary adenocarcinoma : Four case reports with brief literature review]. ³⁸	Held L...Rutten A	30478600	2019
36	Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. ³⁸	Kim TS...Kim JJ	30039320	2019
37	[Case of papillary cholangiocarcinoma with curative resection after long-term follow-up]. ³⁸	Takeda A...Kumada T	30626859	2019
38	Recurrent intestinal obstruction in a patient of Peutz-Jeghers syndrome. ³⁸	Kumar S...Goswami P	30880787	2019
39	Thymic papillary adenocarcinoma coexisting with type A thymoma: A case report. ³⁸	Oka S...Tanaka M	30959362	2019
40	Serous Papillary Adenocarcinoma of Unknown Primary in a Recurrent Paravaginal Cyst. ³⁸	Patel K...Lue J	31281694	2019
41	Aggressive Digital Papillary Adenocarcinoma at Atypical Site. ³⁸	Gupta J...Gupta A	30792586	2019
42	Carcinosarcoma of Vater's papilla: case report of a rare neoplasm and review of the literature. ³⁸	Itoyama R...Baba H	30706323	2019
43	Endoscopic submucosal dissection of papillary adenocarcinoma of stomach; protocol for a systematic review and meta-analysis. ³⁸	Bang CS...Baik GH	30593208	2018
44	[Resected Cases of Thyroid Tumor Diagnosed Class Ⅲ by Fine Needle Aspiration Cytology]. ³⁸	Koshiishi H...Ikeda N	30692302	2018
45	Foamy Histiocyte-like Esophageal Adenocarcinoma: Unusual Morphology and Diagnostic Pitfalls. ³⁸	Yin F...Lai J	30275231	2018
46	Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. ³⁸	Kobayashi H...Nabeshima K	30214559	2018
47	Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. ³⁸	Oono Y...Yano T	29500656	2018
48	Adrenal metastasis in sequentially developed combined hepatocellular carcinoma-cholangiocarcinoma: A case report. ³⁸	Nugroho A...Suh KS	30215052	2018
49	[Clinicopathologic features of nasopharyngeal papillary adenocarcinoma]. ³⁸	Zhang L...Kong LF	30122002	2018
50	Aggressive Digital Papillary Adenocarcinoma: Population-Based Analysis of Incidence, Demographics, Treatment, and Outcomes. ³⁸	Rismiller K...Knackstedt TJ	29578881	2018

Sources

Genes for Papillary Adenocarcinoma

Genes related to Papillary Adenocarcinoma (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	NKX2-1	NK2 Homeobox 1	Protein Coding	30.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17967658 16084450
2	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	28.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1333852 12498221
3	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	24.63	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18339419 9234924 17933139
4	KRT7	Keratin 7	Protein Coding	23.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	22.77	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
6	TP53	Tumor Protein P53	Protein Coding	22.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	21.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	21.59	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
9	PGR	Progesterone Receptor	Protein Coding	21.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	CDH1	Cadherin 1	Protein Coding	20.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	19.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11895489 8629400 1327687 (more) 7889481
12	MST1R	Macrophage Stimulating 1 Receptor	Protein Coding	17.67	GeneCards inferred via : Disorders (show sections)
13	VIM	Vimentin	Protein Coding	17.05	GeneCards inferred via : Publications (show sections)

Sources

Variations for Papillary Adenocarcinoma

Sources

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Sources

Pathways for Papillary Adenocarcinoma

Pathways related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Cytoskeletal Signaling ⁴	12.28	VIM MUC1 KRT7 CDH1
2	MicroRNAs in cancer ³⁷	12.27	VIM TP53 ERBB2 BRCA1
3	Glioma ³⁷ Show member pathways Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.25	TP53 ERBB2 CDH1 BRCA2 BRCA1
4	DNA Damage ⁴	12.23	VIM TP53 BRCA2 BRCA1
5	Adhesion ⁴	11.79	MUC1 CEACAM5 CDH1
6	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	11.77	TP53 PGR ERBB2 CDH1 BRCA2 BRCA1
7	Interleukin-4 and 13 signaling ⁶⁶	11.74	VIM TP53 MUC1
8	Integrated Breast Cancer Pathway ¹	11.64	TP53 CDH1 BRCA2 BRCA1
9	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.53	TP53 BRCA2 BRCA1
10	Platinum drug resistance ³⁷	11.44	TP53 ERBB2 BRCA1
11	Bladder cancer ³⁷ ¹	11.41	TP53 ERBB2 CDH1
12	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.32	TP53 ERBB2 BRCA1
13	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	10.83	TP53 BRCA1
14	TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition ¹	10.79	VIM CDH1
15	a6b1 and a6b4 Integrin signaling ¹	10.62	MST1R ERBB2 CDH1

Sources

GO Terms for Papillary Adenocarcinoma

Cellular components related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	lateral element	GO:0000800	8.62	BRCA2 BRCA1

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.72	TP53 NKX2-1 CDH1 BRCA2 BRCA1
2	positive regulation of gene expression	GO:0010628	9.35	VIM TP53 NKX2-1 ERBB2 BRCA1
3	cellular response to indole-3-methanol	GO:0071681	9.26	CDH1 BRCA1
4	chordate embryonic development	GO:0043009	9.16	BRCA2 BRCA1
5	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	8.92	TP53 MUC1 BRCA2 BRCA1

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.93	VIM TP53 PGR NKX2-1 MUC16 MUC1
2	enzyme binding	GO:0019899	9.35	TP53 PGR NKX2-1 MST1R BRCA1
3	identical protein binding	GO:0042802	9.23	VIM TP53 PGR ERBB2 CEACAM5 CDH1

Sources

Sources for Papillary Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia